EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Infliximab for Refractory Diffuse Sclerosing Osteomyelitis of the Mandible Associated With Ulcerative Colitis: A Case Report

Mayumi Yao, Kyoichi Obata iD, Kensuke Takei iD, Yoshitaka Miyake, Mamoru Fujishima, Koji Kishimoto

Clinical Case Reports · 2026-11 · 14 (11)

DOI: 10.1002/ccr3.73892 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 09.11.2026. Verfasst von Mayumi Yao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery Tsuyama Chuo Hospital Tsuyama Japan. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse sclerosing osteomyelitis (DSO) of the mandible is a chronic nonbacterial inflammatory bone disease. We report a 65‐year‐old woman with ulcerative colitis who presented with swelling and pain of the left mandible. The lesion was refractory to tooth extraction, prolonged antibiotics, and nonsteroidal anti‐inflammatory drugs. CT showed widespread loss of trabecular structure and osteosclerosis, and bone scintigraphy demonstrated abnormal uptake confined to the mandible, without findings suggestive of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. DSO was diagnosed based on the overall clinical course, progressive radiological findings, persistence despite treatment of the suspected odontogenic foci and repeated antibiotic therapy, and supportive histopathological findings. Anti‐tumor necrosis factor‐α (TNF‐α) therapy was considered for the refractory DSO, and infliximab was selected because it is also effective for ulcerative colitis; her symptoms resolved promptly, and imaging showed marked improvement with restoration of trabecular bone. No relapse or treatment‐related adverse events occurred during 3 years of follow‐up. The clinical and radiographic improvement observed following infliximab treatment in this older adult raises the possibility that TNF‐α‐mediated inflammatory pathways may be involved in refractory DSO associated with ulcerative colitis and supports further investigation of anti‐TNF‐α therapy in this setting.

Schlagwörter

Stichwörter der Autor:innen

anti‐TNF‐α therapydiffuse sclerosing osteomyelitisinfliximabulcerative colitis

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgery Tsuyama Chuo Hospital Tsuyama Japan.
  • Department of Oral and Maxillofacial Surgery Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan.
  • Department of Internal Medicine Tsuyama Chuo Hospital Tsuyama Japan.
  • Department of Clinical Pathology Tsuyama Chuo Hospital Tsuyama Japan.
  • Department of Radiology Tsuyama Chuo Hospital Tsuyama Japan.
  • Department of Oral and Maxillofacial Surgery Mitoyo General Hospital Kanonji Japan.

ORCID-Profile: Kyoichi Obata, Kensuke Takei

Zitieren

APA

Yao, M., Obata, K., Takei, K., Miyake, Y., Fujishima, M., & Kishimoto, K. (2026). Infliximab for Refractory Diffuse Sclerosing Osteomyelitis of the Mandible Associated With Ulcerative Colitis: A Case Report. Clinical Case Reports, 14(11). https://doi.org/10.1002/ccr3.73892

Vancouver

Yao M, Obata K, Takei K, Miyake Y, Fujishima M, Kishimoto K. Infliximab for Refractory Diffuse Sclerosing Osteomyelitis of the Mandible Associated With Ulcerative Colitis: A Case Report. Clinical Case Reports. 2026;14(11). doi:10.1002/ccr3.73892

BibTeX
@article{Yao2026,
  author = {Yao, Mayumi and Obata, Kyoichi and Takei, Kensuke and Miyake, Yoshitaka and Fujishima, Mamoru and Kishimoto, Koji},
  title = {Infliximab for Refractory Diffuse Sclerosing Osteomyelitis of the Mandible Associated With Ulcerative Colitis: A Case Report},
  journal = {Clinical Case Reports},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1002/ccr3.73892}
}
Kostenlos starten →